Heartseed Inc.
Research Heartseed Inc. (219A.T) on Bullrun: market cap JPY 61.71B, P/E 325.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker219A.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 61.71B
- P/E325.9
- Financial periodFY2025
- RevenueJPY 3.03B
- Revenue growth246.4%
- Net incomeJPY 190.61M
- Free cash flowJPY 1.05B
- Gross margin100.0%
Valuation Snapshot
latest market cap is JPY 61.71B; P/E is 325.9.
Peer valuation comparison
Latest P/E is 325.88x versus a Healthcare sector median of 21.69x (1402.3% above).
Latest P/E is 325.88x versus a Japan median of 14.28x (2182.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 3.03B | JPY 190.61M | JPY 1.05B | 100.0% | n/a | JPY 6.84B | JPY 252.00K | JPY 7.19B |
| FY2024 | JPY 873.61M | -JPY 812.73M | -JPY 1.36B | 100.0% | -49.43 | JPY 5.30B | JPY 5.39M | JPY 6.62B |
| FY2023 | JPY 344.73M | -JPY 1.47B | -JPY 1.13B | 100.0% | -106.81 | JPY 4.59B | JPY 11.58M | JPY 5.27B |
| FY2022 | JPY 499.06M | -JPY 1.41B | -JPY 1.92B | 100.0% | -64.22 | JPY 3.99B | JPY 30.98M | JPY 4.73B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 61.71B | 325.9 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Heartseed Inc.
Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Heartseed Inc.'s market cap?
Heartseed Inc.'s market capitalization is JPY 61.71B.
What is Heartseed Inc.'s P/E ratio?
Heartseed Inc.'s price-to-earnings (P/E) ratio is 325.9.
What does Heartseed Inc. do?
Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology.